Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study ; volume:22 ; number:1 ; day:11 ; month:1 ; year:2022 ; pages:1-8 ; date:12.2022
BMC cancer ; 22, Heft 1 (11.1.2022), 1-8, 12.2022
- Urheber
-
Chen, San-Chi
Huang, Yi-Hsiang
Chen, Ming-Huang
Hung, Yi-Ping
Lee, Rheun-Chuan
Shao, Yu-Yun
Chao, Yee
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09173-4
- URN
-
urn:nbn:de:101:1-2022042521383500820086
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, San-Chi
- Huang, Yi-Hsiang
- Chen, Ming-Huang
- Hung, Yi-Ping
- Lee, Rheun-Chuan
- Shao, Yu-Yun
- Chao, Yee
- SpringerLink (Online service)
Ähnliche Objekte (12)
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?